L3VLUP
ProSign in

AVTR · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

AVTRJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • AVTR
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterAVTRJNJ
Q3 202022 holders, $2.7bn30 holders, $26.2bn
Q4 202021 holders, $4.2bn32 holders, $26.6bn
Q1 202115 holders, $4.2bn31 holders, $25.3bn
Q2 202112 holders, $5.2bn37 holders, $25.6bn
Q3 202117 holders, $6.3bn40 holders, $24.1bn
Q4 202116 holders, $6.6bn33 holders, $25.2bn
Q1 202222 holders, $5.5bn35 holders, $28.2bn
Q2 202220 holders, $5.4bn33 holders, $26.9bn
Q3 202223 holders, $2.2bn36 holders, $25.4bn
Q4 202220 holders, $2.0bn35 holders, $27.6bn
Q1 202316 holders, $1.5bn42 holders, $24.5bn
Q2 202314 holders, $1.4bn38 holders, $25.0bn
Q3 202318 holders, $1.9bn37 holders, $18.9bn
Q4 202314 holders, $3.0bn31 holders, $19.0bn
Q1 202416 holders, $3.1bn32 holders, $19.7bn
Q2 202413 holders, $2.1bn35 holders, $20.4bn
Q3 20249 holders, $2.6bn28 holders, $22.3bn
Q4 202411 holders, $2.8bn37 holders, $20.4bn
Q1 202510 holders, $2.2bn32 holders, $20.5bn
Q2 202510 holders, $2.0bn31 holders, $18.4bn
Q3 202510 holders, $1.8bn32 holders, $23.7bn
Q4 20257 holders, $1.8bn29 holders, $27.8bn
Q1 20269 holders, $1.3bn34 holders, $35.6bn
Q2 20265 holders, $1.5bn33 holders, $39.1bn
AVTR

Avantor Inc

Holders
13
Reported value
$2.1bn
Buyers
8
Sellers
8

Breadth 0 among 94 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
JNJ

Johnson & Johnson

Holders
35
Reported value
$20.4bn
Buyers
24
Sellers
8

Breadth +16 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2024

Among the 43 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only AVTR (8)

Balyasny Asset Management LLC, Durable Capital Partners LP, First Eagle Investment Management LLC, Holocene Advisors LP, Moore Capital Management LP, Soros Fund Management LLC, Tudor Investment Corp, Winton Group Ltd

Only JNJ (30)

Acadian Asset Management LLC, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Eisler Capital Management Ltd, Fidelity (FMR LLC), GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, and 5 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →